Stockreport
BMRN or TARS: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
Pharmaceuticals, Inc. (TARS). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits. BioMarin Pharmaceutical has a Zacks Rank of #2 (Buy), while Tarsus Pharmaceuticals, Inc. has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that BMRN likely has seen a stronger improvement to its earnings outlook than TARS has recently. However, value investors will care about much more than just this. Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels. Our Value category highlights
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BMRN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BMRN alerts
BMRN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
NEWS
NEWS
- BioMarin Pharmaceutical (NASDAQ:BMRN) was upgraded by analysts at Canaccord Genuity Group Inc. from a "hold" rating to a "buy" rating. They now have a $98.00 price target on the stock, up previously from $84.00.[MarketBeat]
- Making U.S. biotech more competitive with China's could help rare disease patients, experts say [CNBC][CNBC]
- Does BioMarin Pharmaceutical (BMRN) Price Weakness Contrast With Its Cash Flow Valuation? [Yahoo! Finance][Yahoo! Finance]
- BioMarin Pharmaceutical touts $3.2B 2025 revenue, Voxzogo surge and Amicus deal at JPM Conference [Yahoo! Finance][Yahoo! Finance]
- BioMarin Appoints Arpit Davé Chief Digital and Information Officer [Yahoo! Finance][Yahoo! Finance]
- More
BMRN
SEC Filings
SEC Filings
- 1/12/26 - Form 8-K
- 12/22/25 - Form 8-K
- 12/19/25 - Form 8-K
- BMRN's page on the SEC website
- More